TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -194.81 Million TWD | 30.27% |
| 2022 | -279.38 Million TWD | 41.6% |
| 2021 | -478.37 Million TWD | -155.28% |
| 2020 | -187.39 Million TWD | 67.64% |
| 2019 | -579.01 Million TWD | -79.98% |
| 2018 | -321.71 Million TWD | 38.67% |
| 2017 | -524.55 Million TWD | -86.04% |
| 2016 | -281.96 Million TWD | 40.22% |
| 2015 | -471.68 Million TWD | -67.42% |
| 2014 | -281.73 Million TWD | -11.94% |
| 2013 | -251.67 Million TWD | -21.41% |
| 2012 | -207.29 Million TWD | -1.36% |
| 2011 | -204.52 Million TWD | 14.14% |
| 2010 | -238.2 Million TWD | -7.88% |
| 2009 | -220.81 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -16.03 Million TWD | 73.4% |
| 2024 Q2 | -27.53 Million TWD | -71.66% |
| 2023 Q2 | -47.84 Million TWD | 43.27% |
| 2023 FY | -194.81 Million TWD | 30.27% |
| 2023 Q1 | -84.33 Million TWD | -105.69% |
| 2023 Q4 | -60.28 Million TWD | -925.62% |
| 2023 Q3 | -5.87 Million TWD | 87.71% |
| 2022 Q2 | -78.19 Million TWD | 35.64% |
| 2022 Q1 | -121.5 Million TWD | 59.33% |
| 2022 FY | -279.38 Million TWD | 41.6% |
| 2022 Q4 | -41 Million TWD | -5.97% |
| 2022 Q3 | -38.69 Million TWD | 50.52% |
| 2021 Q4 | -298.71 Million TWD | -283.57% |
| 2021 FY | -478.37 Million TWD | -155.28% |
| 2021 Q1 | 4.91 Million TWD | 105.35% |
| 2021 Q2 | -99.26 Million TWD | -2119.53% |
| 2021 Q3 | -77.87 Million TWD | 21.54% |
| 2020 Q1 | -75.38 Million TWD | 7.74% |
| 2020 FY | -187.39 Million TWD | 67.64% |
| 2020 Q2 | 30.42 Million TWD | 140.36% |
| 2020 Q3 | -46.54 Million TWD | -252.97% |
| 2020 Q4 | -91.8 Million TWD | -97.24% |
| 2019 Q4 | -81.71 Million TWD | 74.7% |
| 2019 Q1 | -90.41 Million TWD | 40.97% |
| 2019 Q2 | -83.57 Million TWD | 7.56% |
| 2019 FY | -579.01 Million TWD | -79.98% |
| 2019 Q3 | -322.95 Million TWD | -286.41% |
| 2018 Q2 | 61.02 Million TWD | -52.05% |
| 2018 Q4 | -153.15 Million TWD | 57.08% |
| 2018 Q3 | -356.83 Million TWD | -684.77% |
| 2018 Q1 | 127.26 Million TWD | 176.37% |
| 2018 FY | -321.71 Million TWD | 38.67% |
| 2017 Q2 | -172.14 Million TWD | -111.97% |
| 2017 FY | -524.55 Million TWD | -86.04% |
| 2017 Q4 | -166.62 Million TWD | -59.35% |
| 2017 Q1 | -81.21 Million TWD | 24.78% |
| 2017 Q3 | -104.56 Million TWD | 39.26% |
| 2016 FY | -281.96 Million TWD | 40.22% |
| 2016 Q4 | -107.96 Million TWD | -121.7% |
| 2016 Q3 | -48.69 Million TWD | 29.72% |
| 2016 Q2 | -69.28 Million TWD | -23.7% |
| 2016 Q1 | -56.01 Million TWD | 49.54% |
| 2015 Q1 | -62.23 Million TWD | 22.72% |
| 2015 FY | -471.68 Million TWD | -67.42% |
| 2015 Q4 | -110.99 Million TWD | 40.66% |
| 2015 Q3 | -187.06 Million TWD | -67.95% |
| 2015 Q2 | -111.37 Million TWD | -78.96% |
| 2014 Q2 | -51.3 Million TWD | 27.68% |
| 2014 FY | -281.73 Million TWD | -11.94% |
| 2014 Q1 | -70.93 Million TWD | 15.16% |
| 2014 Q3 | -78.96 Million TWD | -53.93% |
| 2014 Q4 | -80.53 Million TWD | -1.99% |
| 2013 Q1 | -42.22 Million TWD | 25.42% |
| 2013 Q2 | -42.22 Million TWD | 0.0% |
| 2013 Q3 | -83.61 Million TWD | -98.04% |
| 2013 FY | -251.67 Million TWD | -21.41% |
| 2013 Q4 | -83.61 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 FY | -207.29 Million TWD | -1.36% |
| 2012 Q3 | -56.61 Million TWD | 0.0% |
| 2012 Q4 | -56.61 Million TWD | 0.0% |
| 2011 FY | -204.52 Million TWD | 14.14% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -238.2 Million TWD | -7.88% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | -220.81 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bio Preventive Medicine Corp. | -73.28 Million TWD | -165.825% |
| Genomics BioSci & Tech. Co.,Ltd. | -168.06 Million TWD | -15.913% |
| Advagene Biopharma Co., Ltd. | -92.11 Million TWD | -111.497% |
| Taiwan Bio Therapeutics Co., Ltd | -217.51 Million TWD | 10.437% |
| NaviFUS Corp. | -65.72 Million TWD | -196.384% |
| G&E Herbal Biotechnology Co., Ltd. | 72.4 Million TWD | 369.075% |
| TaiRx, Inc. | -212.29 Million TWD | 8.235% |
| Sinew Pharma Inc. | -170.92 Million TWD | -13.977% |
| Lin BioScience, Inc. | -687.19 Million TWD | 71.651% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.04 Million TWD | -3121.597% |
| Lumosa Therapeutics Co., Ltd. | -238.04 Million TWD | 18.161% |
| Anti-Microbial Savior BioteQ Co., Ltd | -51.78 Million TWD | -276.212% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 251.01 Million TWD | 177.61% |
| AP Biosciences Inc | -339.29 Million TWD | 42.584% |
| Sunmax Biotechnology Co., Ltd. | 625.7 Million TWD | 131.134% |
| RBC Bioscience Corporation | 6.43 Million TWD | 3129.705% |
| Syngen Biotech Co.,Ltd. | 274.82 Million TWD | 170.885% |
| EirGenix Inc. | -915.2 Million TWD | 78.714% |
| Enimmune corporation | -223.74 Million TWD | 12.931% |
| Lukas Biomedical Inc. | -47.35 Million TWD | -311.399% |
| BRIM Biotechnology, Inc. | -688.02 Million TWD | 71.685% |
| 3D Global Biotech Inc. | -57.95 Million TWD | -236.163% |
| Mycenax Biotech Inc. | -682.84 Million TWD | 71.471% |
| TCI GENE Inc. | 11.67 Million TWD | 1768.894% |
| SynCore Biotechnology Co.,Ltd | -38.17 Million TWD | -410.348% |
| Oneness Biotech Co., Ltd. | -1.31 Billion TWD | 85.161% |
| Eusol Biotech Co.,Ltd. | -51.61 Million TWD | -277.444% |
| Feng Chi Biotech Corp. | 22.79 Million TWD | 954.73% |
| NeoCore Technology Co., Ltd. | -64.64 Million TWD | -201.354% |
| TWi Biotechnology, Inc. | -170.68 Million TWD | -14.136% |
| Neith Corporation | -40.03 Million TWD | -386.624% |
| Sunny Pharmtech Inc. | -63.32 Million TWD | -207.66% |
| VBI | -6.6 Million TWD | -2851.22% |
| Ever Supreme Bio Technology Co., Ltd | 539.39 Million TWD | 136.116% |
| GeneReach Biotechnology Corp. | -166.27 Million TWD | -17.165% |
| Shine-On BioMedical Co.,Ltd. | -37.16 Million TWD | -424.176% |
| CHO Pharma, Inc. | -306.08 Million TWD | 36.355% |
| Andros Pharmaceuticals Co.,Ltd | -68.15 Million TWD | -185.817% |
| MegaPro Biomedical Co., Ltd | -127.54 Million TWD | -52.735% |
| Visgeneer Inc. | -19.58 Million TWD | -894.487% |
| Greenyn Biotechnology Co., Ltd | 130.66 Million TWD | 249.092% |
| BioLASCO Taiwan Co., Ltd. | 49.74 Million TWD | 491.633% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -88.08 Million TWD | -121.151% |
| Sagittarius Life Science Corp | -55.03 Million TWD | -253.949% |
| BioGend Therapeutics Co., Ltd. | -156.32 Million TWD | -24.619% |
| GlycoNex Incorporation | -178.36 Million TWD | -9.222% |
| Medigen Biotechnology Corp. | -561.29 Million TWD | 65.293% |
| Pharmosa Biopharm Inc. | 8.45 Million TWD | 2403.808% |
| PharmaEngine, Inc. | 274.65 Million TWD | 170.93% |
| Intech Biopharm Corporation | -337.98 Million TWD | 42.362% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -10.68 Million TWD | -1723.722% |
| BiOptic Inc. | 37.74 Million TWD | 616.094% |
| TaiGen Biopharmaceuticals Holdings Limited | 136.73 Million TWD | 242.477% |
| Senhwa Biosciences, Inc. | -296.3 Million TWD | 34.254% |
| NatureWise Biotech & Medicals Corporation | 10.12 Million TWD | 2025.0% |
| OBI Pharma, Inc. | -1.04 Billion TWD | 81.384% |
| Savior Lifetec Corporation | 30.03 Million TWD | 748.718% |
| Great Novel Therapeutics Biotech & Medicals | -61.54 Million TWD | -216.558% |
| Level Biotechnology Inc. | 62.9 Million TWD | 409.689% |
| Medigen Vaccine Biologics Corporation | -1.15 Billion TWD | 83.204% |
| Meribank Biotech Co., Ltd | -125.34 Million TWD | -55.418% |
| Acepodia, Inc. | -817.31 Million TWD | 76.165% |
| Caliway Biopharmaceuticals Co., Ltd. | -488.45 Million TWD | 60.117% |